© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 18, 2022
John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.
Dr John Allan discusses the adverse events he monitors for with select treatments for chronic lymphocytic leukemia, and when he decides to move to second-line therapy.
An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.
John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.
Dr John Allan gives an overview of the frontline treatment options available for chronic lymphocytic leukemia with reference to clinical trial data.
A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.